DICOT Stock Overview
Engages in the development of pharmaceutical products in Sweden.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Dicot AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.28 |
52 Week High | kr0.42 |
52 Week Low | kr0.096 |
Beta | 1.43 |
1 Month Change | 2.61% |
3 Month Change | 43.60% |
1 Year Change | 118.25% |
3 Year Change | -74.01% |
5 Year Change | -93.93% |
Change since IPO | -96.80% |
Recent News & Updates
Shareholder Returns
DICOT | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 7.0% | 14.3% | -0.9% |
1Y | 118.3% | 85.6% | 14.2% |
Return vs Industry: DICOT exceeded the Swedish Pharmaceuticals industry which returned 85.6% over the past year.
Return vs Market: DICOT exceeded the Swedish Market which returned 14.2% over the past year.
Price Volatility
DICOT volatility | |
---|---|
DICOT Average Weekly Movement | 12.1% |
Pharmaceuticals Industry Average Movement | 9.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DICOT's share price has been volatile over the past 3 months.
Volatility Over Time: DICOT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 3 | Elin Trampe | www.dicot.se |
Dicot AB (publ) engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot AB (publ) Fundamentals Summary
DICOT fundamental statistics | |
---|---|
Market cap | kr224.83m |
Earnings (TTM) | -kr47.85m |
Revenue (TTM) | n/a |
9,999x
P/S Ratio-4.7x
P/E RatioIs DICOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DICOT income statement (TTM) | |
---|---|
Revenue | -kr4.00k |
Cost of Revenue | kr0 |
Gross Profit | -kr4.00k |
Other Expenses | kr47.85m |
Earnings | -kr47.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.059 |
Gross Margin | 100.00% |
Net Profit Margin | 1,196,274.10% |
Debt/Equity Ratio | 0% |
How did DICOT perform over the long term?
See historical performance and comparison